The Refractory Mood Disorders Program, part of the Center of Excellence on Mood Disorders, leads research in the development of innovative treatment options for refractory mood disorders. Refractory, also known as treatment-resistant, describes conditions that do not respond to at least two different medications.
Led by Salih Selek, M.D., our team is currently involved in the following research:
- UTHealth Ketamine Project – A 12-week clinical trial of 8 infusions explores ketamine’s efficacy and safety in treating treatment-resistant depression.
Salih Selek, M.D.
Director, Refractory Mood Disorders Program
UTHealth Harris County Psychiatric Center (HCPC)
2800 S. MacGregor Way
Houston, TX 77021